← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Glycobia, Inc.
Ithaca, NY
$7,311,578
Total funding
14
Grants
Funding over time
peak $2.2M · FY2009–19$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$7,311,578 · 14
By mechanism
R44$4,199,667 · 3
R43$1,812,563 · 9
N44$999,898 · 1
N43$299,450 · 1
Investigators at Glycobia, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
IGF::OT::IGF TOPIC 321 CHEMICALLY DEFINED GLYCAN LIBRARIES FOR REFERENCE STANDARDS AND GLYCOMICS RESEARCH (JOINT NCI-NIGMS PROGRAM)$999,898
N44 · FY2015 · CA
Engineering Escherichia coli for glycosylation of complex human proteins$883,833
R44 · FY2011 · GM
Glycoconjugate therapeutic peptides for improved treatment of human diseases$766,474
R44 · FY2016 · GM
Engineering Escherichia coli for glycosylation of complex human proteins$714,931
R44 · FY2012 · GM
Glycoconjugate therapeutic peptides for improved treatment of human diseases$636,906
R44 · FY2015 · GM
Engineering Escherichia coli for sialylation of therapeutic proteins$602,221
R44 · FY2014 · GM
Engineering Escherichia coli for sialylation of therapeutic proteins$595,302
R44 · FY2015 · GM
Novel strategy to generate glycan-specific antibodies for cancer immunotherapy$300,000
R43 · FY2019 · CA
BOTTOM-UP GLYCOENGINEERING LIBRARY OF N-GLYCANS$299,450
N43 · FY2013 · CA
Therapeutic antibody fragments from glycoengineered Escherichia coli$238,238
R43 · FY2011 · AI
Glycophage arrays for the discovery of biomarkers in disease$200,000
R43 · FY2009 · GM
Conjugation of polysialic acid to biologics in glycoengineered Escherichia coli$199,020
R43 · FY2010 · GM
Glycoconjugate therapeutic peptides for improved treatment of human diseases$197,758
R43 · FY2013 · GM
Production of recombinant human glucocerebrosidase in Escherichia coli$175,860
R43 · FY2011 · GM
Therapeutic antibody fragments from glycoengineered Escherichia coli$153,496
R43 · FY2010 · AI
N-glycan specific antibodies for advancing glycobiology research$150,000
R43 · FY2017 · GM
Humanizing N-linked glycosylation in Escherichia coli$115,988
R43 · FY2009 · GM
Glycosylation of full-length antibodies in Escherichia coli$82,203
R43 · FY2009 · GM